Pregabalin Capsule
Product Images NDC 72162-1542

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 72162-1542). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721621542)

Pregabalin Capsules 50 mg oral dosage form label showing a package size of 90 capsules. The label includes the NDC 72162-1542, states the product is repackaged by Bryant Ranch Prepack, Inc., and manufactured by ScieGen Pharmaceuticals Inc. Storage instructions and a warning to keep the drug out of reach of children are also present.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, showing varying levels of pain improvement across the doses.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing percent improvement in pain from baseline between Pregabalin 100 mg three times a day and placebo. The x-axis represents percent improvement in pain, and the y-axis represents percent of patients improved. Two lines depict treatment groups, showing greater improvement with Pregabalin over placebo.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph illustrating the percent of patients improved relative to percent improvement in pain from baseline for Pregabalin at doses of 300 mg, 150 mg, 75 mg twice daily, and placebo. The y-axis shows the percent of patients improved (0 to 100%), and the x-axis indicates percent improvement in pain from baseline (0 to 100%). Multiple lines compare the effectiveness of different dosages and placebo in improving patient pain.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, with Pregabalin 200 mg showing the highest improvement over the range.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph illustrates the relative efficacy of the two Pregabalin dosing regimens compared to placebo in pain improvement.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar graph comparing responder rates (%) in two studies (E1 and E3) of pregabalin at various dosages versus placebo. The x-axis shows dosage groups, including placebo and pregabalin doses (50 mg/day up to 600 mg/day) with BID or TID regimens, and the y-axis shows responder rate percentages. Statistically significant increases versus placebo are marked.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph depicting seizure reduction as median percentage change from baseline relative to pregabalin dose in mg/day, with data points from four studies (E1 BD, E2 TID, E3 BD, and E3 TID). The y-axis shows seizure reduction percentage, and the x-axis shows dose up to 600 mg/day. Significant p-values are indicated for various points.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. Four lines represent different treatments: Pregabalin 800 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo. The graph compares pain improvement outcomes across these dosage levels and placebo.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing the estimated percentage of subjects without LTR over 180 days between Pregabalin and placebo groups. The y-axis represents the estimated percentage of subjects without LTR from 0% to 100%, and the x-axis shows time in days from 0 to 180. The Pregabalin group shows a higher percentage of subjects without LTR throughout the period compared to the placebo group, indicated by distinct solid and dashed lines, respectively.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved from baseline to Week 12 BOCF between Pregabalin and placebo. The x-axis represents percent improvement from 0 to 100%, while the y-axis shows the percent of subjects improved from 0 to 100%. Two lines are displayed: a solid line for Pregabalin and a dotted line for placebo, illustrating higher improvement percentages for Pregabalin across the range.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph showing percent of subjects improved on the vertical axis versus percent improvement from baseline to week 16 BOCF on the horizontal axis. The graph compares improvement rates between Pregabalin and Placebo groups with Pregabalin represented by a solid line and Placebo by a dashed line, indicating greater improvement with Pregabalin across increasing improvement percentages.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

The image shows a formula used to calculate creatinine clearance (CLcr). It includes variables for age in years, weight in kilograms, serum creatinine in mg/dL, and a factor of 0.85 applied for female patients.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure diagram of pregabalin showing its molecular arrangement with labeled functional groups including an amino group and a carboxyl group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.